References
- Abrams, D., J. Hilton, R. Leiser, S. Shade, and T. Elbeik. 2003. Short-term effects of cannabinoids in patients with HIV-infection. Annals of Internal Medicine 139 (4):258–66. doi: 10.7326/0003-4819-139-4-200308190-00008.
- Australian Institute of Health and Welfare (AIHW). 2002. 2001 national drug strategy household survey: First results. AIHW cat. no. PHE 35. Drug Statistics Series No. 9. Canberra. http://www.aihw.gov.au/publication-detail/?id=6442467340
- Beaulieu, P., and M. A. Ware. 2007. Reassessment of the role of cannabinoids in the management of pain. Current Opinions in Anaesthesiology 20 (5):473–77. doi:10.1097/ACO.0b013e3282efd175.
- Bonn-Miller, M. O., M. T. Boden, M. M. Bucossi, and K. A. Babson. 2014. Self-reported cannabis use characteristics, patterns and helpfulness among medical cannabis users. American Journal of Drug and Alcohol Abuse 40 (1):22–30. doi:10.3109/00952990.2013.821477.
- Bonn-Miller, M. O., A. J. Heinz, E. V. Smith, R. Bruno, and S. Adamson. 2016. Preliminary development of a brief cannabis use disorder screening tool: The cannabis use disorder identification test short-form. Cannabis and Cannabinoid Research 1 (1):252–61. doi:10.1089/can.2016.0022.
- Cichewicz, D. L., and E. A. McCarthy. 2003. Antinociceptive synergy between delta (9)-tetrahydrocannabinol and opioids after oral administration. Journal of Pharmacology and Experimental Therapeutics 304 (3):1010–15. doi:10.1124/jpet.102.045575.
- Colizzi, M., and S. Bhattacharyya. 2017. Does cannabis composition matter? Differential effects of delta-9-tetrahydrocannabinol and cannabidiol on human cognition. Current Addiction Reports 4 (2):62–74. doi:10.1007/s40429-017-0142-2.
- Doblin, R., and M. Kleiman. 1991. Marijuana as antiemetic medicine: A survey of oncologists’ experiences and attitudes. Journal of Clinical Oncology 9 (7):1314–19. doi:10.1200/JCO.1991.9.7.1314.
- Erickson, P. G., D. M. Riley, Y. W. Cheung, and P. A. O’Hare, eds. 2015. Harm reduction: A new direction for drug policies and programs. Toronto, ON: University of Toronto Press.
- Eyler, A. A., J. F. Chriqui, S. Moreland-Russell, and R. C. Brownson. 2016. Prevention, policy, and public health. New York, NY: Oxford Press.
- Governors Highway Safety Association (GHSA). 2015. Drug-impaired driving: A guide for what states can do. Retrieved from http://www.ghsa.org/html/files/pubs/GHSA_DruggedDrivingt2015_R5_LoRes.pdf
- Grinspoon, L., and J. B. Bakalar. 1997. Marihuana: The forbidden medicine. New Haven, CT: Yale University Press.
- Hazekamp, A., M. A. Ware, K. R. Muller-Vahl, D. Abrams, and F. Grotenhermen. 2013. The medicinal use of cannabis and cannabinoids—an international cross-sectional survey on administration forms. Journal of Psychoactive Drugs 45 (3):199–210. doi:10.1080/02791072.2013.805976.
- Loflin, M., M. E. Earleywine, and M. O. Bonn-Miller. 2017. Medicinal versus recreational cannabis use: Patterns of cannabis use, alcohol use, and cued-arousal among veterans who screen positive for PTSD. Addictive Behaviors 68:18–23. doi:10.1016/j.addbeh.2017.01.008.
- Lucas, P. 2012. Cannabis as an adjunct to or substitute for opiates in the treatment of chronic pain. Journal of Psychoactive Drugs 44 (2):125–33. doi:10.1080/02791072.2012.684624.
- National Conference of State Legislatures (NCSL). 2017. Marijuana overview. Washington, DC: Author. http://www.ncsl.org/research/civil-and-criminal-justice/marijuana-overview.aspx.
- Nunberg, H., B. Kilmer, R. Pacula, and J. Burgdorf. 2011. An analysis of applicants presenting to a medical marijuana specialty practice in California. Journal of Drug Policy Analysis 4 (1):1–16. doi:10.2202/1941-2851.1017.
- Ogborne, A. C., R. G. Smart, T. Weber, and C. Birchmore-Timney. 2000. Who is using cannabis as a medicine and why: An exploratory study. Journal of Psychoactive Drugs 32 (4):435–43. doi:10.1080/02791072.2000.10400245.
- Reiman, A. 2007. Medical cannabis patients: Patient profiles and healthcare utilization patterns. Complementary Health Practice Review 12 (1):31–50. doi:10.1177/1533210107301834.
- Reiman, A. 2009. Cannabis as a substitute for alcohol and other drugs. Harm Reduction Journal 6 (35). doi: 10.1186/1477-7517-6-35.
- Reinarman, C., H. Nunberg, F. Lanthier, and T. Heddleston. 2011. Who are medical marijuana patients? Population characteristics from nine California assessment clinics. Journal of Psychoactive Drugs 43 (2):128–35. doi:10.1080/02791072.2011.587700.
- Russo, E. B. 2013. Cannabis and cannabinoids: Pharmacology, toxicology, and therapeutic potential. Oxford, UK: Routledge.
- Szabo, B., S. Siemes, and I. Wallmichrath. 2002. Inhibition of GABAergic neurotransmission in the ventral tegmental area by cannabinoids. European Journal of Neuroscience 15 (12):2057–61. doi:10.1046/j.1460-9568.2002.02041.x.
- Toothaker, L. E. 1993. Multiple comparison procedures. Newbury Park, CA: Sage.
- Wesner, B. 1996. The medical marijuana issue among PWAS: Reports of therapeutic use and attitudes towards legal reform. Working Paper Series. Manoa, HI: Drug Research Unit, University of Hawaii.
- Woolridge, E., S. Barton, J. Samuel, J. Osorio, A. Dougherty, and A. Holdcroft. 2005. Cannabis use in HIV for pain and other medical symptoms. Journal of Pain and Symptom Management 29 (4):358–67. doi:10.1016/j.jpainsymman.2004.07.011.